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Abstract
Obesity has reached epidemic proportions worldwide. Several animal models of obesity exist, but studies are lacking that
compare traditional lard-based high fat diets (HFD) to ‘‘Cafeteria diets’’ (CAF) consisting of nutrient poor human junk food.
Our previous work demonstrated the rapid and severe obesogenic and inflammatory consequences of CAF compared to
HFD including rapid weight gain, markers of Metabolic Syndrome, multi-tissue lipid accumulation, and dramatic
inflammation. To identify potential mediators of CAF-induced obesity and Metabolic Syndrome, we used metabolomic
analysis to profile serum, muscle, and white adipose from rats fed CAF, HFD, or standard control diets. Principle component
analysis identified elevations in clusters of fatty acids and acylcarnitines. These increases in metabolites were associated with
systemic mitochondrial dysfunction that paralleled weight gain, physiologic measures of Metabolic Syndrome, and tissue
inflammation in CAF-fed rats. Spearman pairwise correlations between metabolites, physiologic, and histologic findings
revealed strong correlations between elevated markers of inflammation in CAF-fed animals, measured as crown like
structures in adipose, and specifically the pro-inflammatory saturated fatty acids and oxidation intermediates laurate and
lauroyl carnitine. Treatment of bone marrow-derived macrophages with lauroyl carnitine polarized macrophages towards
the M1 pro-inflammatory phenotype through downregulation of AMPK and secretion of pro-inflammatory cytokines.
Results presented herein demonstrate that compared to a traditional HFD model, the CAF diet provides a robust model for
diet-induced human obesity, which models Metabolic Syndrome-related mitochondrial dysfunction in serum, muscle, and
adipose, along with pro-inflammatory metabolite alterations. These data also suggest that modifying the availability or
metabolism of saturated fatty acids may limit the inflammation associated with obesity leading to Metabolic Syndrome.
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Introduction
Over 1 billion people worldwide and two-thirds of the US
population are overweight or obese [1,2]. Obesity and insulin
resistance are strongly associated with the infiltration of adipose
tissue by inflammatory cells [3–7]. The factors that induce
immune cells to infiltrate adipose tissue are unknown, but may
be related to free fatty acid release from adipocytes [8]. Lipolysis
and serum non-esterified fatty acids (NEFA) are elevated with
obesity, insulin resistance, trauma, or infection [9–12]. Further-
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38812more, cytokines associated with obesity and insulin resistance such
as tumor necrosis factor a (TNFa) can drive lipolysis and fatty acid
release from adipose [13,14].
HFD and saturated fatty acid intake correlate with Metabolic
Syndrome [15–18]; while polyunsaturated fatty acids have been
shown to improve insulin sensitivity, as well as lessen inflammation
[19–22]. Saturated fatty acids are known to be pro-inflammatory
through activating pattern recognition receptors including Toll-
like receptors (TLR) and/or G-protein coupled receptors (GPCR)
[23]. Therefore, we hypothesized that saturated fatty acids and
metabolites derived from mitochondrial oxidation may be
biomarkers that predict inflammatory response and insulin
resistance in diet-induced obesity. Previous metabolomic work
by our group identified biochemical markers or predictors of
pathologic states such as Metabolic Syndrome, cardiovascular
disease (CVD), insulin resistance, and other metabolic defects [24–
28]. Here we have applied comprehensive metabolic profiling to
compare a HFD that is typically used in diet-induced obesity
studies with CAF diet, revealing diet-specific alterations in several
metabolites, notably lauroyl carnitine. We then evaluated the
effects of lauroyl carnitine on macrophage pro-inflammatory
responses, with findings that implicate lauroyl carnitine as a
mediator of obesity-induced inflammation.
Materials and Methods
Animals
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of Duke University. Male Wistar rats (approximately
200 grams (g), 7–8 weeks old) (Harlan Laboratories, Dublin, VA)
were housed 2 rats per cage in a 12 hour light/dark cycle and
acclimated to the Duke animal housing facility on ad libitum
undefined standard chow 7001 (‘‘SC’’, Harlan Teklad Lab Animal
Diets SC7001) for 2 weeks before assignment to one of four
experimental diet groups. Upon initiation of experimental diets,
rats (avg. 300 g, 9–10 weeks old) were either maintained on ad
libitum SC as controls or switched to experimental diets: ad libitum
defined 45% fat chow (High fat diet ‘‘HFD’’, Research Diets
D06011802), the matched low fat chow control (Low fat diet
‘‘LFD’’ Research Diets D07010502), or a cafeteria diet (‘‘CAF’’)
with 3 human snack foods varied daily in addition to ad libitum SC
as previously described [12]. Fat intake was the largest macronu-
trient alteration in CAF-fed rats, however simple carbohydrate
consumption was also elevated over HFD and SC-fed rats groups
[12]. Complete characterization of CAF, HFD, LFD and SC-fed
rats including all diet details, food intake, weight gain, serum
measures (insulin, glucose, total NEFA), other physiologic mea-
sures, adipose mass, as well as histology for liver, pancreas,
epididymal white adipose tissue (eWAT), and brown adipose is
presented in Sampey et al. [12]. Briefly summarizing that work,
CAF-fed rats displayed the most severe obesity, glucose intolerance
and inflammation compared to HFD, LFD and SC- fed rodents.
Diet Studies
SC and CAF-fed rats were fed diets for 10 weeks and at sacrifice
plasma, serum, or tissue was isolated for metabolomic analysis
(study 1; n=4–12 per diet, per group as indicated in Figures and
Tables). Analyses included total NEFA, individual serum NEFA,
acylcarnitine and amino acid metabolite profiling of serum, as well
as acylcarnitine, organic acid, and amino acid profiling of liver and
muscle. A subsequent group of experimental animals (n=4–5 per
diet) were fed SC, LFD, HFD, and CAF diets for 15 weeks and
metabolites (amino acids, organic acids, acylcarnitines, and free
carnitine) were isolated from eWAT (study 2).
Metabolomic Analysis
Serum (50 mL) and tissue [liver (100 mg), muscle (100 mg), or
adipose (200 mg)] were used for metabolic profiling. Tissues were
reconstituted in 4 volumes of deionized/distilled water for a 5-fold
dilution. Samples were then immediately homogenized on ice at
25,000 RPM for 20 seconds (setting 5.5 on the VDI-12 homog-
enizer). Samples were mixed well by vortex and 100 mL was taken
immediately for acylcarnitine (AC), amino acid (AA) and free
carnitine analysis. Metabolomic measure of AC, AA, and carnitine
is well-established in human and rodent models [27–35]. Methods
for sample preparation are as described previously [27,35]. Briefly,
measurement of free carnitine, AC, and AA in serum and eWAT
was completed by direct-injection electrospray tandem mass
spectrometry (MS/MS), using a Micromass Quattro Micro liquid
chromatography (LC)-MS system (Waters-Micromass, Milford,
Figure 1. Serum accumulation of NEFA and acylcarnitine
metabolites in CAF compared to SC-fed. Aged-matched male rats
were fed diets for 10 weeks and serum was isolated in 6 hour-fasted
rats. (n=8 SC, 9 CAF). Amino acids and acylcarnitine mitochondrial
intermediates were measured by LC-MS/MS. Non-esterified fatty acids
(NEFA) were measured enzymatically. Metabolites indicate fold change
of metabolites from CAF-fed serum compared to mean of SC-fed serum
(CAF/SC) for each metabolite, which indicate accumulation (red) of
many NEFAs and acylcarnitine species with decreases (green) in amino
acids, arachidonoyl carnitine (C20:4), and short chain acylcarnitines in
the serum from CAF-fed rats (FDR 3.88%). See Table S4 for full names of
metabolites.
doi:10.1371/journal.pone.0038812.g001
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38812Figure 2. Serum myristate correlates to Metabolic Syndrome measures: weight gain, HOMA-IR, and blood glucose. Aged-matched
male rats were fed diets for 10 weeks and serum was isolated in 6 hour-fasted rats and metabolites measured as in Figure 1 (n=8 SC, 9 CAF). A)
Serum concentrations of individual NEFAs indicate that of the eight fatty acids measured, seven were significantly elevated in CAF-fed rats versus SC
controls. (*p=0.04, #p=0.01,ˆp,0.0001). B–D) Serum saturated fatty acid myristic acid (C14:0) significantly correlated with weight gain (B), HOMA-IR
(C) and blood glucose at sacrifice (D).
doi:10.1371/journal.pone.0038812.g002
Figure 3. Lipotoxicity and mitochondrial dysfunction induced by CAF diet in muscle. Aged-matched male rats were fed diets for 15 weeks
and tissue was isolated from animals sacrificed after a 6 hour fast. A) Muscle triglyceride levels were doubled in CAF-fed rats compared to SC-fed
controls (*p,0.02, n=4 SC, 5 CAF). B) Acylcarnitines accumulate in muscle of CAF-fed rats compared to SC controls (*p#0.02). Metabolites measured
and tissue isolation as in Figure 1. (n=8 SC, 9 CAF for B). See Table S4 for full names of metabolites.
doi:10.1371/journal.pone.0038812.g003
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(Leap Technologies, Carrboro, NC, USA), a model 1525 HPLC
solvent delivery system (Agilent Technologies, Palo Alto, CA,
USA), and a data system running MassLynx 4.0 software (Waters
Corporation, Milford, MA) as described [26,27,36]. NEFA were
measured in serum enzymatically (Wako, Richmond, VA, USA)
using the Hitachi 911 clinical chemistry analyzer (Hitachi, Tokyo,
Japan) [12]. Table S4 provides the full names of acylcarnitines,
organic acid, and amino acids analyzed.
Hierarchical Clustering and Heat Map Generation
Metabolites were selected that had complete data in at least
80% of experiments. Missing data was imputed using k-nearest
neighbors with k=8. SC was used as a reference, and each
metabolite value was divided by the average metabolite value in
SC diet. Ratios are presented as log2 (test diet/SC). For serum in
Study 1, filtered metabolite data were analyzed by the one-class
Significance Analysis of Microarrays (SAM) algorithm [37] to
select the maximum set of metabolites whose expression levels
were significantly different in test vs. SC given false discovery rate
(FDR) of less than 5%. Data are presented as log2(fold change)
relative to SC. Heat maps were generated using the R software
package (http://www.r-project.org/).
Statistics, Principle Component Analysis, and
Bioinformatics Analysis
First, serum, muscle, liver and white adipose metabolites were
compared by analysis of variance (ANOVA) within each depot
(serum or tissue). For each group, the list of p-values comparing
test diets to control diet (one per metabolite) was then used to
compute an FDR p-value. P-values adjusted for multiple
comparisons less than 0.05 were considered statistically significant
(all metabolite values and FDR p-values in Tables S1, S2, and S3
for serum, muscle, and eWAT, respectively). All analyses were
performed using SAS Version 9.2 (SAS Institute, Cary NC).
Second, serum metabolites were examined by Principle Compo-
nent Analysis (PCA) on each metabolite class. Pareto scaling was
applied to the concentration data to normalize the effects of the
large dynamic range of the metabolites [38,39]. The cross
validated standard error was calculated for each metabolite in
the first PCA loadings component. If the magnitude of the error
was less than the absolute value of the loadings, then the
contribution of that metabolite was considered significant. The
concentration of serum C2 acylcarnitine was not significantly
different between the two diet groups, and therefore, it was
excluded from the acylcarnitine model. Finally, Spearman
pairwise correlation coefficients were calculated for each metab-
olite from study 1 with adjustments for multiple comparisons
Figure 4. Severe mitochondrial dysfunction in CAF-fed white adipose tissue. A) Diet-induced mitochondrial dysfunction was evident in
CAF-fed rat epididymal adipose, which was greater than dysfunction in HFD-fed animals. CAF-diet increased levels of multiple acylcarnitines when
compared to HFD-, LFD-, and SC- fed animals demonstrating mitochondrial dysfunction (*p#0.03 SC v. CAF;ˆp,0.02 LFD v HFD). B) Lauroyl carnitine
(‘‘LC’’, C12-AC) specifically elevated by CAF diet (A) is significantly correlated to crown like structure (CLS) accumulation, a hallmark of adipose
inflammation. Aged-matched male rats were fed diets for 15 weeks and tissue was isolated from animals sacrificed after a 6 hour fast. (n=4, SC, LFD
and HFD, n=5 CAF). See Table S4 for full names of metabolites.
doi:10.1371/journal.pone.0038812.g004
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time of sacrifice, weight gain, or homeostatic model assessment of
insulin resistance (HOMA-IR) and significant correlations were
presented using Benjamini-Hochberg FDR). For adipose tissue,
Spearman pair-wise correlation coefficients were calculated with
adjustments for multiple comparisons and significant correlations
were presented using Benjamini-Hochberg FDR between metab-
olites and three parameters (blood glucose at the time of sacrifice,
weight gain, or crown like structures). All Spearman statistical
analyses were carried out using the R software package. Student’s
t-test was used to compare single measures where appropriate.
Lauroyl Carnitine Treatment of Macrophages
Bone marrow derived macrophages (BMDM) were isolated
from 8 week old male C57Bl/6 mice, plated and cultivated on
non-tissue culture treated 10 cm dishes for 6 days in RPMI-1640
supplemented with 30% L929 fibroblast (ATCC CCL-1)-condi-
tioned media (containing M-CSF), 10% fetal bovine serum (FBS,
Sigma-Aldrich, St. Louis, MO), 2 mM L-glutamine, and 100
units/mL penicillin G sodium, 100 mg/mL streptomycin sulfate
(Life Technologies, Carlsbad, CA). BMDMs were trypsinized at
day 6 and plated onto 10 cm tissue culture treated dishes. BMDM
cells were treated the next day with fresh media for unpolarized
macrophages (M0), 5 ng/mL lipopolysaccharide (LPS) plus
10 ng/mL interferon gamma (IFNc) to drive the pro-inflamma-
tory (M1) phenotype [40], or 20 and 200 mM doses of lauroyl
(C12) L-carnitine (Avanti Polar Lipids, Inc., Alabaster, Alabama)
for 24 hours. Protein lysates were isolated in 1% Triton-X 100,
0.05% sodium dodecal sulfate (SDS) and protease/phosphatase
inhibitors (Sigma) and then quantified by BCA (Pierce) using a
BioRad680 microplate reader and software.
Western Immunoblot
Protein lysates were separated using SDS-polyacrylamide gel
electrophoresis (PAGE) in a BioRad mini-PROTEAN Tetra-Cell
unit, transferred to PVDF membranes using a BioRad Trans Blot
Turbo transfer system, and blocked with 5% bovine serum
albumin (BSA) in Tris-buffered saline with 0.2% Tween-20
(TBST) at room temperature for 1 hr. Primary antibodies were
diluted according to the manufacturer guidelines in TBST with
5% BSA and applied to PVDF blots overnight at 4uC while
rocking. Antibodies against phosphorylated AMP-activated pro-
tein kinase (AMPK), total AMPK (Cell Signaling, Danvers, MA),
or actin (Millipore/Chemicon, Billerica, MA) were used according
to the manufacturer’s protocols. Horse radish peroxidase (HRP)-
conjugated secondary goat-anti-rabbit antibodies and enhanced
chemiluminescence (ECL) reagents (GE Healthcare Piscataway,
NJ) were used to generate digital images acquired using the
Versadoc multi-imaging system (BioRad). Bands were quantified
using ImageJ software (BioRad) and reported as pAMPK/AMPK
normalized to actin.
Secreted Cytokine Profiling
BMDM were isolated as above, plated into 24 well plates and
either treated with growth media for unstimulated macrophages
(M0), 5 ng/mL LPS and 10 ng/mL IFNc to polarize to the pro-
inflammatory M1 phenotype, or 10–1000 mM lauroyl carnitine to
mimic the obese adipose environment. After 24 hrs, conditioned
media was isolated and assayed using Proteome Profiler Array
Mouse Cytokine array panel A (R and D Systems, Inc.
Minneapolis, MN) according to the manufacturer’s protocol.
Briefly, media was collected following treatments, centrifuged to
remove cells and cellular debris at 14,000 g for 10 minutes, and
the supernatant was frozen at280uC until the assay was
Figure 5. Lauroyl carnitine drives pro-inflammatory macrophage response. A) Primary bone marrow derived macrophages (BMDM) were
treated with media alone for unpolarized macrophages ‘‘M0’’, 5 ng/mL LPS plus 10 ng/mL interferon gamma (IFNc) to drive the pro-inflammatory
‘‘M1’’ phenotype [40], or 20 and 200 mM doses of lauroyl L-carnitine (‘‘LC’’) for 24 hours. Western immunoblot using antibodies against
phosphorylated AMP-activated protein kinase (AMPK), total AMPK, or actin. B) Bands are quantified using Image J and shown as pAMPK/AMPK
normalized to actin. C) BMDM were treated for 24 hours with M1-polarizing cytokines (LPS/ IFNc) or 10–1000 mM LC. Secreted cytokines were profiled
from BMDM using Proteome Profiler Array Mouse Cytokine array (*p,0.05 relative to M0).
doi:10.1371/journal.pone.0038812.g005
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treatment group (n=3) was then combined with the Detection
Antibody Cocktail and allowed to mix 1hr, incubated overnight on
membranes, and visualized with streptavidin-horse radish perox-
idase (HRP) and ECL (GE Healthcare). Digital images were
captured and quantified using the Versadoc 4000 (BioRad) and
relative abundance with background subtracted was normalized to
internal standards.
Results
Hierarchical clustering and principle component analysis
of serum metabolites predict biomarkers of CAF-induced
pathology
Serum metabolites can be predictive of insulin resistance and
cardiovascular disease, including elevations in acylcarnitines and
branched chain amino acids (BCAA) [28,41–47]. Supervised
cluster analysis was performed to elucidate patterns of serum
metabolic changes in CAF vs. SC-fed animals. This cluster analysis
implicates upregulation of many NEFAs and acylcarnitine species
with downregulation of several amino acids, arachidonoyl
carnitine (C20:4), and short chain acylcarnitines in CAF-fed rats
(FDR 3.88%, Fig. 1). Accumulation of acylcarnitines is indicative
of inefficient beta-oxidation and mitochondrial dysfunction
[27,36]. All metabolite quantities and statistics are shown in
Table S1.
To further identify relevant biomarkers associated with junk-
food diet-induced obesity we used principal component analysis to
identify clusters of metabolites that change coordinately in serum
from rats exposed to the SC or CAF diets. Samples from each diet
group are clustered together in each scores plot (principle
component 1 (PC1), horizontal axis, Fig. S2A–C). Several fatty
acids contribute to PC1, including the highly prevalent oleic acid
(C18:1) and linoleic acid (C18:2). Interestingly, three of the eight
NEFAs contributing to PC1 are pro-inflammatory saturated fatty
acids elevated in the CAF diet-fed rodents: stearate (C18:0),
palmitate (C16:0) and myristate (C14:0) (Fig. 1 and Fig. S2A).
Several acylcarnitine intermediates were identified that contribut-
ed to PC1 separation of SC vs. CAF including medium or short
chain acylcarnitines such as dodecenoyl carnitine (C12:1), tiglyl
carnitine (C5:1), tetradecenoyl carnitine (C14:1), lauroyl carnitine
(C12) and propionyl carnitine (C3) (Fig. 1 and Fig. S2B). All values
and FDR p-values adjusted for multiple comparisons are
presented in Table S1. Thus, PC1 is defined by widespread
changes in a number of metabolic pathways, but with particularly
strong changes in fatty acid metabolism.
Dramatic weight gain in obese CAF-fed rats significantly
elevates serum NEFA levels that correlate with
physiologic measures of Metabolic Syndrome
Supervised cluster and PCA analysis of serum metabolites
indicated that several serum NEFAs drove separation between SC
and CAF-fed rats (Fig. 1 and Fig S1). Previous work by our group
demonstrated elevated total NEFA levels in CAF-fed rats
compared to HFD, LFD and SC-fed rats [12]. Here, we profiled
individual NEFAs. Seven out of eight measured NEFA are
significantly elevated in CAF-fed compared to SC-fed rats,
including three saturated fatty acids (Fig. 2A). Spearman pairwise
correlation coefficients were calculated to identify which metab-
olites predict the severity of Metabolic Syndrome phenotypes.
Seventy-one metabolites were profiled from the serum metabo-
lome including the sum NEFA, individual NEFAs, and multiple
acylcarnitines and amino acids (Table S1). Metabolites were
correlated with physiologic parameters including weight gain,
blood glucose at time of sacrifice, and homeostatic model
assessment of insulin resistance (HOMA-IR) as reported in
Sampey et al. [12]. After adjustments for multiple comparisons
between metabolites and physiologic measures, the elevated molar
sum of serum NEFA in CAF-fed obese rats correlated weakly with
HOMA-IR (r=0.53, p=0.029, FDR=0.2), and most strongly
with blood glucose (r=0.71, p=0.0013, FDR=0.05) and weight
gain (r=0.73, p=0.0012, FDR=0.05) (Figures S2A–C, respec-
tively). Among individual serum NEFAs, myristic acid (C14:0) was
most significantly correlated with weight gain (r=0.81, p=0.0001,
FDR=0.05), glucose (r=0.66, p=0.0038, FDR=0.1), and
HOMA-IR (r=0.53, p=0.027, FDR=0.2) (Fig. 2B–D). Greater
weight gain, glucose levels, and HOMA-IR are indicators of
insulin resistance and Metabolic Syndrome [48]. Taken together
our data suggest, at least in rat models, thresholds may be set
including serum levels above 5 mM for myristic acid (C14:0) and
225 mM for NEFAs above which elevated risk of components of
Metabolic Syndrome is present. Interestingly, serum palmitoleic
acid (C16:1), a lipokine associated with improved insulin sensitivity
and metabolic status in rodents and patients [49–51], was present
at high levels in CAF-fed rats, and was positively correlated with
poor metabolic status including weight gain (r=0.60, p=0.01,
FDR=0.1), elevated blood glucose (r=0.61, p=0.01, FDR=0.1),
Figure 6. Cafeteria diet drives accumulation of oxidative
intermediates and pro-inflammatory lipid mediators. Rats were
fed SC or CAF diets for 10 weeks and at sacrifice serum and was isolated
for metabolomic analysis including total and individual non-esterified
fatty acids (NEFA), acylcarnitine and amino acid metabolite profiling of
serum and muscle. To compare the effects of traditional defined lard-
based diets with a CAF model on adipose metabolism, rats were fed SC,
low fat and high fat lard-based defined diets, or CAF diet for 15 weeks
and metabolites were analyzed. A. Metabolomic profiling has revealed
that CAF diet-induced obesity drives accumulation of non-esterified
fatty acids (NEFA), triglycerides (TG), and fatty acid b-oxidation
intermediates in serum, muscle and for the first time white adipose
tissue. CAF-mediated effects in adipose are more exaggerated than
lard-based HFD effects. B. Lauroyl carnitine, an adipose-derived
biomarker identified through metabolomic profiling was demonstrated
to drive polarization of primary bone marrow derived macrophages
(BMDM) towards the pro-inflammatory ‘‘M1’’ phenotype. Taken
together, CAF diet proved to be a rapid and dramatic inducer of
insulin resistance, components of Metabolic Syndrome, and metabolic
biomarkers. In CAF-diet-induced obese adipose, lauroyl carnitine was
identified as a potential mediator between metabolism of saturated
fatty acids and the pro-inflammatory response.
doi:10.1371/journal.pone.0038812.g006
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(correlation images not shown).
Metabolic markers of saturated fatty acids and other
biomarkers correlate with poor metabolic status
Just as the serum NEFA myristate (C14:0) correlated with
markers of Metabolic Syndrome (Fig. 2B–D), elevated levels of
serum AC derived from myristic acid (myristoyl carnitine, C14–
AC) also significantly correlated with markers of poor metabolic
status including blood glucose (r=0.63, p=0.007, FDR=0.1),
NEFA (r=0.56, p=0.02, FDR=0.1), and weight gain (r=0.56,
p=0.02, FDR=0.2). Another serum saturated fatty acid, lauric
acid was not independently measured in this study, but the lauric
acid-derived serum acylcarnitine (lauroyl carnitine, C12-AC) was
elevated in CAF-fed rat serum and correlated with blood glucose
(r=0.56, p=0.02, FDR=0.2) and weight gain (r=0.65,
p=0.005, FDR=0.1) (values reported in Table S1, correlation
images not shown).
Alterations in acylcarnitines derived from branched chain
amino acid (BCAA) catabolism are reflected by changes in small
chain acylcarnitines C3, C4, C5 and related metabolites [28].
Cluster analysis of serum in Figure 1 suggested that C3, C4 and
C5 metabolites are relevant in CAF versus SC comparisons and
are downregulated by CAF diet exposure. C5 acylcarnitines are
comprised of a-methylbutyrylcarnitine and isovalerylcarnitine
species which equilibrate with intermediates in BCAA isoleucine
and leucine catabolism, respectively, while C3 acylcarnitine
represents propionyl CoA, an intermediate of isoleucine and
valine catabolism. Interestingly, in our CAF diet model, PCA
identified C3-AC and C5-DC as serum biomarkers delineating the
SC and CAF groups (Fig. S1B). Serum propionyl carnitine (C3-
AC) was consistently decreased by CAF feeding (Fig. 1 and
Tables S1, S2, S3, although this difference only reached statistical
significance by ANOVA accounting for multiple comparisons in
muscle). Interestingly, plasma C3 and C5 acylcarnitines are
elevated in plasma of obese and insulin resistant humans in concert
with elevations in BCAA, and feeding a HFD actually causes these
intermediates to decrease in plasma [28], consistent with the
current findings. However, our data also shows that levels of C3
acylcarnitines are significantly increased in skeletal muscle of CAF-
fed rats, consistent with the concept that BCAA can contribute to
overload of mitochondrial metabolism [28,52].
Diet-induced mitochondrial dysfunction was evident in
muscle of CAF-fed rats
Muscle lipid accumulation has been associated with mitochon-
drial dysfunction in mice made obese by a traditional lard-based
HFD [36]. To examine if CAF-diet also induced mitochondrial
dysfunction, acylcarnitine profiles were evaluated in muscle
compared to SC-diet. We have previously published that rats fed
CAF diet gained an average of 100 g more than SC after just
10 weeks on diet, with substantial lipid accumulation in liver,
white and brown adipose tissue [12]. CAF-fed white and brown fat
pads were 3-fold heavier than SC-fed rats and contained elevated
macrophage infiltration [12]. In addition, livers of CAF-fed rats
displayed severe pan-lobular microsteatosis and large inflamma-
tory loci [12]. Here we also report that after 10 weeks on diet,
muscle triglyceride content was elevated by two-fold compared to
SC-fed rats (Fig. 3A, p=0.017). Furthermore, Figure 3B demon-
strates accumulation of a subset of muscle acylcarnitines
comprised of short, medium and long chain species in CAF-fed
rodents compared to SC-fed controls indicative of mitochondrial
dysfunction, as was also found in serum (Fig. 1 and Table S1). All
muscle metabolite quantities and statistics are shown in Table S2.
Liver metabolites did not demonstrate significant alterations in
metabolic profiles of AA, OA, or AC by ANOVA (data not
shown). Note the aforementioned increase in muscle C3
acylcarnitines in CAF-fed animals.
Adipose tissue displayed diet-induced mitochondrial
dysfunction
We hypothesized that metabolism in adipose tissue might be
defective as it is the major tissue associated with storage and
release of lipids as well as chronic obesity-induced inflammation.
Therefore, we next completed a 15 week diet study on rats fed
four different diets. Our previous reports demonstrate that
epididymal white adipose tissue (eWAT) from CAF-fed animals
are inflamed and display elevations in inflammatory markers such
as macrophage aggregates (crown-like structures) and elevated
pro-inflammatory cytokine TNFa expression in the macrophage-
enriched stromal-vascular fraction [53]. In addition to CAF and
SC diets as above, rodents were fed two additional diets most
frequently used in diet-induced obesity studies: 10% kcal-derived
from fat (low fat diet, LFD); and 45% kcal-derived from lard-based
fat (high fat diet, HFD) so that CAF diet and its control can be
compared directly to HFD and LFD. The CAF-fed rats gained
nearly 250 grams more weight than SC-fed rats over 15 weeks
[12]. LFD and HFD rats displayed metabolic parameters and
gained weight in an intermediate range compared to SC and CAF
diet-exposed animals (75 g and 100 g greater than SC, respec-
tively) [12]. After 15 weeks on diet, eWAT was isolated and
metabolomic profiling of amino acids, organic acids, acylcarni-
tines, and free carnitine was conducted on fat (Table S3). CAF diet
induced dramatic mitochondrial dysfunction in eWAT as
evidenced by increased levels of multiple medium and long chain
acylcarnitines when compared to SC-fed control animals with
fewer alterations evident in HFD-fed eWAT acylcarnitines versus
LFD (Fig. 4A and Table S3). ANOVA analysis of the four diets
revealed lauroyl carnitine (C12-AC) as the most significantly
regulated metabolite with levels in CAF-fed rodent adipose over
two-fold greater than in HFD, LFD or SC-fed tissue (false
discovery rate (FDR) p-value adjusted for multiple comparisons
p=0.00069). Compared to LFD, HFD feeding significantly
increased acylcarnitines C16:0, C18:0 and C18:1, while CAF-diet
exposure increased C10, C12, C18:1 and C18 compared to SC
(Fig. 4A and Table S3).
Adipose lauroyl carnitine correlates with physiologic and
histologic measures of Metabolic Syndrome and
inflammation
Spearman pairwise correlation coefficients were calculated with
adjustments for multiple comparisons between metabolites and
physiologic measures of blood glucose at time of sacrifice, weight
gain, or NEFA. Adipose lauric acid acylcarnitine (lauroyl
carnitine, C12-AC) correlated significantly with blood glucose
(r=0.76, p=0.0004, FDR=0.1). In our previous work, we
examined histologic markers of adipose inflammation denoted
by crown like structures (CLS), which have been shown to
correlate with obesity, insulin resistance, and adipose inflamma-
tion. CLS per 10X field were 15.3-, 2.75-, 1.5-fold higher in CAF
diet-fed rat fat pads compared to SC, LFD and HFD, respectively
[12]. Spearman pairwise correlations revealed that lauroyl
carnitine also positively correlated with CLS (r=0.69, p=0.002,
FDR=0.05, Fig. 4B). Interestingly, lauroyl carnitine did not
correlate with inflammatory loci in livers (not shown and Sampey
et al. [53]). Overall, in our model, levels above 5 pmol/mg tissue
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38812for lauroyl carnitine in epididymal white adipose correlated with
risk factors for Metabolic Syndrome.
Lauroyl carnitine-mediated inflammation of BMDM
The identification of the NEFA laurate and acylcarnitine
metabolite lauroyl carnitine as biomarkers associated with
obesity, insulin resistance, and inflammation in CAF-fed rodents
led us to investigate if lauroyl carnitine plays a causal role in
these associations. Macrophages are an integral component of
adipose tissue with less inflammatory macrophages resident in
lean tissue and pro-inflammatory macrophages infiltrating with
increasing obesity [6,7,54]. Since lauroyl carnitine was specifi-
cally elevated in CAF-fed adipose tissue, we treated primary
BMDM with increasing doses of lauroyl carnitine to provide
mechanistic insight regarding macrophage inflammation in
adipose tissue. Resident M2 macrophages are reliant upon fatty
acid metabolism and AMPK activity [40,55]. Sag et al.
demonstrated that activation of AMPK (i.e. phosphorylation)
drives anti-inflammatory polarization in macrophages [55].
Figure 5 demonstrates that 24 hours of LPS and IFNc pro-
inflammatory M1 polarization of BMDM caused a clear decrease
in AMPK phosphorylation. Treatment with 200 mM lauroyl
carnitine also caused a decrease in AMPK phosphorylation to
levels similar to those in M1 BMDMs. Cytokine array analyses of
conditioned media revealed that M1 polarization of BMDMs
drove expression of the pro-inflammatory cytokines TNFa,
RANTES (CCL5), IL-6, CXCL9, and CCL4 (not shown and
Fig. 5C). Interestingly, lauroyl carnitine increased expression of
several cytokines, in a dose-dependent fashion that approximated
levels present with cytokine-stimulated M1 polarization of
BMDM. While lauroyl carnitine did not dramatically regulate
all cytokines associated with obesity and inflammation, it did
upregulate the pro-inflammatory cytokines IL-3, IL-12, IL-16,
IL-23, CXCL11, CXCL13, RANTES, and CCL17 (Fig. 5C)
that primarily regulate chemotaxis, demonstrating a direct C12-
AC-mediated activation of pro-inflammatory cytokines.
Discussion
Recent work has demonstrated that metabolomic analysis can
provide a view of mitochondrial function that reflects the
physiologic or pathophysiologic state of the system [26,27,36,56].
Acylcarnitines have traditionally been used to measure inborn
errors of metabolism, but in recent years have been shown to be
markers of insulin resistance [24]. Acylcarnitines in particular are
valuable biomarkers because they represent byproducts of fat,
glucose, and amino acid mitochondrial oxidation. The work
presented here contributes to increasing evidence that elevated
acylcarnitines may act as biomarkers of insulin resistance,
cardiovascular disease (CVD), defects in fat metabolism, as well
as inflammation in Metabolic Syndrome [27,28,36,43]. We
further provide evidence and mechanistic insight of how one
biomarker, lauroyl carnitine, may mediate inflammation associat-
ed with obesity in adipose.
We observed that CAF-fed animals had higher levels of pro-
inflammatory saturated fatty acids such as C12 (laurate) and C14
(myristate), as well as the acylcarnitine derivatives lauroyl carnitine
and myristoyl carnitine. Obesity-associated increases in circulating
fatty acids cause functional impairments in several cell types
including hepatocytes, skeletal muscle, cardiomyocytes, b-cells,
endothelial cells and adipocytes [57]. Emerging evidence also
implicates mitochondrial dysfunction as a potentially unifying
mechanism underlying these observations. Koves et al. have
shown that obesity and/or overnutrition impose a persistent lipid
burden on muscle mitochondria, resulting in a mismatch between
b-oxidation and tricarboxylic acid cycle activity [58]. This
disconnect results in high rates of incomplete fatty acid b-
oxidation and increases in acylcarnitines, which correlated with
impaired muscle insulin sensitivity and glucose metabolism [26].
Acylcarnitine accumulation, or mitochondrial dysfunction, can be
improved with exercise or in rodent models of improved glucose
tolerance [26,58]. In line with our observations, others have shown
saturated fatty acids such as myristate correlate with obesity,
cholesterol, and lower levels of adiponectin in human populations
[59–62]. In contrast, some have shown fatty acids such as
palmitoleic acid to attenuate insulin resistance in mouse models
and correlate with some beneficial lipid measures in human studies
[49–51]; interestingly in our rat model palmitoleic acid was
positively correlated with markers of Metabolic Syndrome and
insulin resistance, which suggests that this may be a species-specific
finding.
It is well-accepted that obese adipose tissue is in a state of
persistent low level inflammation and that increasing obesity
drives further inflammation and subsequent insulin resistance
[63]. Although strong links between dyslipidemia, obesity, and
inflammation are established, little is known about mediators of
adipose inflammation [3,4]. We demonstrated that lauroyl
carnitine, a biomarker identified through metabolomics, is one
such mediator. Lauroyl carnitine inhibited AMPK activation, a
pathway known to promote an anti-inflammatory M2 macro-
phage phenotype associated with insulin sensitivity [55]. In fact,
the inhibition was similar to that observed with M1 polarization.
Interestingly, Garvey et al. recently showed in the RAW264.7
macrophage cell line that lauroyl carnitine can activate NFKB
signaling [64]. Using a cytokine profiling assay, we further report
increased pro-inflammatory and chemotactic cytokine secretion
following lauroyl carnitine exposure in primary BMDMs that
reflects the M1 proinflammatory phenotype. Thus, our findings
suggest that lauroyl carnitine may act as a pro-inflammatory
lipokine through AMPK pathway de-activation. Future studies
will need to be conducted to determine in vivo relevance of the
role of lauroyl carnitine on adipose microenvironment inflam-
mation.
While the effects of lauroyl carnitine appear to be profound,
several mechanistic details remain uncertain. Signaling through
pattern recognition receptors including TLRs and GPCRs have
been implicated in saturated fatty acid-mediated inflammation,
especially lauric acid TLR-mediated activation of NFKB through
the MyD88 pathway [23,65–77]; it is unclear if lauroyl carnitine
can also activate these receptors. It is likely that CAF-diet induces
a feed-forward loop which includes increased intake of saturated
fatty acids, as well as elevated caloric intake in general, which
together act to drive obesity, release the pro-inflammatory
metabolite lauroyl carnitine, and promote inflammation concur-
rently. Hence the elevated acylcarnitines present in CAF-fed rats,
both systemically and in tissues, are not only markers of the
potential inflammatory state, but may act as mediators to
specifically promote inflammation.
In summary, this study included a comprehensive analysis of
physiologic, metabolic, and histologic measures between a
commonly used dietary model for diet-induced obesity, lard-based
HFD, and its LFD control, compared to an alternative human
junk food-based dietary model, the CAF diet. Findings presented
herein and in our previous work demonstrate that the CAF diet
results in a more dramatic phenotype of obesity and related
metabolic abnormalities compared to traditional HFD [12].
Compared to traditional lard-based diets commonly used in
rodent diet-induced obesity studies, which are high in saturated
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many components associated with Metabolic Syndrome, including
fat (saturated and trans-fats), sodium, and cholesterol, plus is low in
protective nutrients such as fiber and micronutrients. While the
effects of CAF diet are dramatic, no causal associations can be
inferred for a specific component in our studies. Figure 6
summarizes our findings: metabolomic analysis identified a CAF
biomarker signature consistent with rapid-onset Metabolic Syn-
drome and elevated mitochondrial dysregulation that corresponds
to weight gain, HOMA-IR measures of insulin sensitivity,
hyperglycemia, pro-inflammatory macrophage infiltration of
adipose and crown-like structure formation. Further, we demon-
strate that one metabolite that was significantly elevated in CAF-
adipose tissue, lauroyl carnitine, can drive the pro-inflammatory
activation of macrophages. The CAF diet, while not traditionally
utilized, may be superior to HFD to model modern human obesity
trends including exposure to energy-dense, nutrient-poor diets,
early and rapid obesity development, and elevated markers of
Metabolic Syndrome and inflammation.
Supporting Information
Figure S1 Principle component (PC) analysis of the
serum metabolome. Principle component analysis for each
metabolite class was carried out, NEFA, acylcarnitine and amino
acids (A–C, respectively). The scores plots reveal a distinct
metabolic perturbation in each metabolite class between the
standard chow- (SC, white square) and the Cafeteria- (CAF, black
circle) fed rat samples primarily along the first component 1. The
percent variation explained by the two principle components for
each model is shown on the axes in parentheses. See Table S4 for
full names of acylcarnitines and amino acids. (n=8 SC, 9 CAF).
(TIF)
Figure S2 NEFAs are elevated in CAF-fed rats and
correlate with markers of Metabolic Syndrome:
HOMA-IR, blood glucose, and weight gain. The molar
sum of NEFAs significantly correlates with HOMA-IR (A), blood
glucose at sacrifice (B), and weight gain (C). Aged-matched male
rats were fed SC or CAF diets for 10 weeks and serum was isolated
in 6 hour fasted rats. (n=8 SC, 9 CAF).
(TIFF)
Table S1 Serum metabolites. Numbers are mean 6 SEM.
N=8 for SC and 9 for CAF. P-values are calculated by ANOVA,
false discovery rate (FDR) p-value adjusted for multiple compar-
isons (empty wells are non-significant).
(TIFF)
Table S2 Muscle tissue metabolites. Numbers are mean 6
SEM. N=12 for SC and 9 for CAF. P-values are calculated by
ANOVA, false discovery rate (FDR) p-value adjusted for multiple
comparisons (empty wells are non-significant).
(TIFF)
Table S3 Epididymal white adipose tissue metabolites.
Numbers are mean 6 SEM. N=4 for all groups, except n=5 in
CAF. P-values are calculated by Student’s t-test (empty wells are
non-significant).
(TIFF)
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